We are unyielding in our pursuit of life-changing therapies and our grit and compassion lead us to fight for a better future for patients and their families.
We believe there is tremendous potential in the area of targeting the immune system through the gut microbiome. By working with the microbiome rather than replacing it, Kaleido is in a unique position to unlock an untapped area of science with unprecedented new treatments.
We believe there is tremendous potential in the area of targeting the immune system through the gut microbiome. By working with the microbiome rather than replacing it, Kaleido is in a unique position to unlock an untapped area of science with unprecedented new treatments.
Location: United States, Massachusetts, Lexington
Employees: 51-200
Total raised: $166M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Aberdare V... | aberdare.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 29.06.2018 | Series C | $101M | - |
| 18.09.2017 | - | $65M | - |
Mentions in press and media 13
| Date | Title | Description |
| 31.07.2024 | Canva's Bold Move: Acquiring Leonardo AI to Transform Creative Design | In a world where creativity meets technology, Canva has made a significant leap. The design platform, beloved by millions, has acquired Leonardo AI, an Australian startup specializing in generative artificial intelligence. This acquisition ... |
| 30.07.2024 | Canva Acquires Leonardo.ai: AI Design Powerhouse Takes Shape | By Joseph Henry Published Jul 30, 2024 10:13AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard Share on Pocket Canva, the design platform used by millions worldwide, has announced a strategic acqu... |
| 05.10.2021 | Kaleido Biosciences : Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis | KB295 reached its primary endpoint demonstrating favorable safety and tolerability profile Reduction in key ulcerative colitis biomarkers correlated with disease activity and inflammation - fecal calprotectin, fecal lactoferrin, and FimH - ... |
| 09.08.2021 | Kaleido Biosciences : Announces New Chairperson Appointment to its Board of Directors | LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve huma... |
| 21.04.2021 | KALEIDO BIOSCIENCES, INC. Kaleido Biosciences : Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT) in Preventing Febrile Neutropenia | LEXINGTON, Mass. - Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to treat disease and improve human health, today announced a research collabo... |
| 29.06.2018 | Kaleido raises $101 million to target microbiome | “We think about the microbiome as a single organ,” said President and COO Alison Lawton in a phone interview. “And that single organ pumps out different metabolites. Our chemistries are targeted at the function of the organ and its output.”... |
| 26.06.2018 | Kaleido brings in $101M in series C for its microbiome-wide therapy pipeline | Kaleido Biosciences has raked in $101 million in series C financing, after coming out of stealth last September with $65 million, with the goal of developing novel chemistries that direct the human microbiome and its various bacteria as a w... |
| 25.06.2018 | Kaleido Biosciences Raises $101 Million Series C Financing | BEDFORD, Mass.--(BUSINESS WIRE)--Kaleido Biosciences, a clinical-stage healthcare company leading the development of novel chemistries to drive functions of the microbiome organ, today announced that it has closed $101 million in an oversub... |
| 25.06.2018 | Kaleido brings in $101M in series C for its microbiome-wide therapy pipeline | Kaleido Biosciences has raked in $101 million in series C financing, after coming out of stealth last September with $65 million, with the goal of developing novel chemistries that direct the human microbiome and its various bacteria as a w... |
| 18.09.2017 | Flagship seeks $500M for sixth fund; unveils another microbiome firm | Cambridge, MA-based venture capital group Flagship Pioneering has filed a $500 million offering with the Securities & Exchange Commission to set up a sixth investment fund. The VC, which was founded in 2000 and has around 30 investments... |
Show more